Systemic Lupus Erythematosus - Pipeline Review, H1 2018

Publisher Name :
Date: 31-May-2018
No. of pages: 446
Inquire Before Buying

Systemic Lupus Erythematosus - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H1 2018, provides an overview of the Systemic Lupus Erythematosus (Immunology) pipeline landscape.

"Systemic lupus erythematosus (SLE) is an autoimmune disease that causes a chronic inflammatory condition. The inflammation triggered by SLE affect many organs in the body, including skin, joints, kidneys, brain, and other organs. Several factors have been associated with the disease such as genetics, environment and gender and hormones. Symptoms can vary and can change over time. Common symptoms include severe fatigue, painful or swollen joints, headaches, rash on cheeks and nose called butterfly rash, hair loss and anemia."

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Lupus Erythematosus (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 10, 30, 25, 41, 5 and 3 respectively. Similarly, the Universities portfolio in Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 8 and 1 molecules, respectively.

Systemic Lupus Erythematosus (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus (Immunology).

- The pipeline guide reviews pipeline therapeutics for Systemic Lupus Erythematosus (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Systemic Lupus Erythematosus (Immunology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Systemic Lupus Erythematosus (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Lupus Erythematosus (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Systemic Lupus Erythematosus (Immunology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus (Immunology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Systemic Lupus Erythematosus - Pipeline Review, H1 2018

Table of Contents
Table of Contents 2
Introduction 6
Systemic Lupus Erythematosus - Overview 7
Systemic Lupus Erythematosus - Therapeutics Development 8
Systemic Lupus Erythematosus - Therapeutics Assessment 24
Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development 36
Systemic Lupus Erythematosus - Drug Profiles 69
Systemic Lupus Erythematosus - Dormant Projects 415
Systemic Lupus Erythematosus - Discontinued Products 422
Systemic Lupus Erythematosus - Product Development Milestones 424
Appendix 432

List of Tables
Number of Products under Development for Systemic Lupus Erythematosus, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Systemic Lupus Erythematosus - Pipeline by AbbVie Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by ACEA Biosciences Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by AiCuris GmbH & Co KG, H1 2018
Systemic Lupus Erythematosus - Pipeline by Amgen Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Apellis Pharmaceuticals Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Araim Pharmaceuticals Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Asahi Kasei Pharma Corp, H1 2018
Systemic Lupus Erythematosus - Pipeline by Atlantic Bio Sci LLC, H1 2018
Systemic Lupus Erythematosus - Pipeline by Aurinia Pharmaceuticals Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Bio-Path Holdings Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Biogen Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Biotest AG, H1 2018
Systemic Lupus Erythematosus - Pipeline by Boehringer Ingelheim GmbH, H1 2018
Systemic Lupus Erythematosus - Pipeline by Boston Pharmaceuticals Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Bristol-Myers Squibb Co, H1 2018
Systemic Lupus Erythematosus - Pipeline by Carna Biosciences Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Celgene Corp, H1 2018
Systemic Lupus Erythematosus - Pipeline by Cells for Cells SA, H1 2018
Systemic Lupus Erythematosus - Pipeline by Corestem Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by CuraVac Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Deltanoid Pharmaceuticals Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Domainex Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by Eisai Co Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by Eli Lilly and Co, H1 2018
Systemic Lupus Erythematosus - Pipeline by Epsilon-3 Bio Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by Galapagos NV, H1 2018
Systemic Lupus Erythematosus - Pipeline by Genentech Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Genosco Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Genovax Srl, H1 2018
Systemic Lupus Erythematosus - Pipeline by Gilead Sciences Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by GlaxoSmithKline Plc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by HanAll Biopharma Co Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by Idorsia Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by Immungenetics AG, H1 2018
Systemic Lupus Erythematosus - Pipeline by Immunomedics Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Immunwork Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Immupharma Plc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Invion Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by Janus Biotherapeutics Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Johnson & Johnson, H1 2018
Systemic Lupus Erythematosus - Pipeline by K-Stemcell Co Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by Kezar Life Sciences Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by Lead Discovery Center GmbH, H1 2018
Systemic Lupus Erythematosus - Pipeline by LSK BioPartners Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by MedAnnex Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by MedImmune LLC, H1 2018
Systemic Lupus Erythematosus - Pipeline by Merck & Co Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Merck KGaA, H1 2018
Systemic Lupus Erythematosus - Pipeline by Millennium Pharmaceuticals Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Mount Tam Biotechnologies Inc, H1 2018
Systemic Lupus Erythematosus - Pipeline by Nektar Therapeutics, H1 2018
Systemic Lupus Erythematosus - Pipeline by Neovacs SA, H1 2018
Systemic Lupus Erythematosus - Pipeline by Nippon Chemiphar Co Ltd, H1 2018
Systemic Lupus Erythematosus - Pipeline by Novartis AG, H1 2018
Systemic Lupus Erythematosus - Pipeline by Nuevolution AB, H1 2018
Systemic Lupus Erythematosus - Pipeline by Omeros Corp, H1 2018
Systemic Lupus Erythematosus - Pipeline by Pfizer Inc, H1 2018

List of Figures
Number of Products under Development for Systemic Lupus Erythematosus, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018
  • Global Enzyme Replacement Therapy Market Growth (Status and Outlook) 2019-2024
    Published: 22-Feb-2019        Price: US 3660 Onwards        Pages: 136
    Enzyme replacement therapy (ERT) is a medical treatment which replaces an enzyme that is deficient or absent in the body. Usually, this is done by giving the patient an intravenous (IV) infusion of a solution containing the enzyme. The classification of enzyme replacement therapy includes injectable agents and oral agents, and the revenue proportion of injectable agents in 2017 is about 62.38%, and the proportion is in increasing trend from 2013 to 2017. North America is the larges......
  • Liver Disease Treatment Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 22-Feb-2019        Price: US 3000 Onwards        Pages: 145
    Liver Disease Treatment Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Liver Disease Treatment industry with a focus on the Chinese market. The report provides key statistics on the market status of the Liver Disease Treatment manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of 2014-2024 global and Ch......
  • Global Infantile Spasms Therapeutics Market Growth 2019-2024
    Published: 22-Feb-2019        Price: US 3660 Onwards        Pages: 130
    An infantile spasm (IS), also known as West Syndrome, is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood. West Syndrome is characterized by infantile spasms, developmental regression, and a specific pattern on electroencephalography (EEG) testing called hypsarrhythmia (chaotic brain waves). The onset of infantile spasms is usually in the first year of life, typically between 4-8 months. The seizures primarily consist of a sudden bending forward of the body with s......
  • Microbiome Drugs Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 21-Feb-2019        Price: US 3000 Onwards        Pages: 136
    Microbiome Drugs Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Microbiome Drugs industry with a focus on the Chinese market. The report provides key statistics on the market status of the Microbiome Drugs manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of 2014-2024 global and Chinese Microbiome Drug......
  • Musculoskeletal Disorders Therapeutics Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 20-Feb-2019        Price: US 3000 Onwards        Pages: 147
    Musculoskeletal Disorders Therapeutics Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Musculoskeletal Disorders Therapeutics industry with a focus on the Chinese market. The report provides key statistics on the market status of the Musculoskeletal Disorders Therapeutics manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides a......
  • Global Anti-inflammatory Therapeutics Market Research Report 2019
    Published: 20-Feb-2019        Price: US 2900 Onwards        Pages: 90
    Anti-inflammatory therapeutics are primarily used to reduce inflammation. These drugs are types of analgesics that are used for reducing pain. The global anti-inflammatory therapeutics market will grow steadily at a CAGR of over 6% by 2021. This market research analysis identifies the increase in the prevalence of immune-mediated inflammatory disease (IMID) as one of the primary growth factors for this market. IMID includes a group of disabling conditions that share a common inflammatory ......
  • Global Microbiome Therapeutics Market Growth 2019-2024
    Published: 20-Feb-2019        Price: US 3660 Onwards        Pages: 175
    The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bact......
  • Global Acute Ischemic Stroke Therapeutics Market Research Report 2019
    Published: 20-Feb-2019        Price: US 2900 Onwards        Pages: 98
    AIS is a chronic condition characterized by the sudden loss of blood supply to a part of the brain, thus causing subsequent loss of neurological function. AIS is caused by thrombotic or embolic obstruction of the cerebral artery and is more common than hemorrhagic stroke. The global AIS therapeutics market is expected to register a low single digit market growth during the forecast period. The marginal growth rate is attributed to the lack of approved drugs in this area, the presence of alternat......
  • Global Venous Leg Ulcers Treatment Market Insights, Forecast to 2025
    Published: 19-Feb-2019        Price: US 3900 Onwards        Pages: 118
    The global Venous Leg Ulcers Treatment market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Venous Leg Ulcers Treatment market based on company, product type, end user and key regions. This report studies the global market size of Venous Leg Ulcers Treatment in key regions like North America, Europe, Asia Pacific, Central & South......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs